<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00824837</url>
  </required_header>
  <id_info>
    <org_study_id>02975</org_study_id>
    <secondary_id>AHHREC02975</secondary_id>
    <nct_id>NCT00824837</nct_id>
  </id_info>
  <brief_title>Study of beta2-Microglobulin Removal by Standard Versus New High Cut-Off Haemodialysis Membrane</brief_title>
  <acronym>HiCOF</acronym>
  <official_title>Randomised, Cross Over Pilot Study Comparing Removal of beta2-Microglobulin by Standard Haemodialysis to Haemodialysis With a Novel Dialysis Membrane (P2SH) in Chronic Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Austin Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Austin Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a novel haemodialysis membrane, compared
      with the standard dialysis membrane, will increase the removal of beta2-microglobulin in
      chronic dialysis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite advances in treatment of kidney diseases, morbidity and mortality of chronic dialysis
      patients remains unsatisfactory. Standard haemodialysis membranes remove middle-sized
      molecule solutes poorly such as beta2-microglobulin, which has a pathogenic role in
      dialysis-related amyloidosis. Pre-dialysis beta2-microglobulin concentration has been shown
      to be independently predictive of mortality. A new polyamide haemodialysis membrane has been
      developed with increased pore size to increase the removal of middle-sized uraemic toxins
      such as beta2-microglobulin. This study aims to evaluate the effectiveness of the new
      membrane in beta2-microglobulin removal compared with standard haemodialysis membrane in
      dialysis patients and the degree of increased loss of albumin as a potential limiting factor
      of its use.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Beta2-microglobulin removal by new larger pore membrane versus standard haemodialysis membrane</measure>
    <time_frame>5 weeks (2 weeks in each arm, 1-week washout period)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Albumin loss with the use of new larger pore membrane compared with standard haemodialysis membrane</measure>
    <time_frame>5 weeks (2 weeks in each arm, 1-week washout period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Removal of low-molecular-weight solutes by new larger pore membrane versus standard haemodialysis membrane</measure>
    <time_frame>5 weeks (2 weeks in each arm; 1-week washout period)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Renal Dialysis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>New larger pore membrane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard haemodialysis membrane</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Larger pore haemodialysis membrane</intervention_name>
    <description>Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Gambro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard haemodialysis membrane</intervention_name>
    <description>Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic haemodialysis patients for more than 2 years

          -  Urine output &lt;100 mL per day

          -  3 haemodialysis sessions per week

          -  Permanent arteriovenous dialysis access

        Exclusion Criteria:

          -  Serum albumin &lt;25 g/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rinaldo Bellomo, MBBS,MD,FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director Intensive Care Research, Austin Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2009</study_first_submitted>
  <study_first_submitted_qc>January 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2009</study_first_posted>
  <last_update_submitted>July 6, 2009</last_update_submitted>
  <last_update_submitted_qc>July 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Rinaldo Bellomo</name_title>
    <organization>Austin Health</organization>
  </responsible_party>
  <keyword>beta 2 microglobulin</keyword>
  <keyword>haemodialysis</keyword>
  <keyword>albumin</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

